- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02700048
Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single center, single-blinded randomized cross over design trial, that will compare the impact of IN naloxone vs. IN saline during experimental hypoglycemia on day one on the responses to experimental hypoglycemia on day two. 18 participants will be studied twice, 8 weeks apart. On each occasion participants will undergo a 2 hour hypoglycemic clamp (target 50 mg/dl) in the morning and in the afternoon on day one and then again on the morning of day 2. During the morning clamps, samples will be collected for later measurement of serum epinephrine, glucagon and cortisol levels and participants will be asked to complete a hypoglycemia symptom questionnaire. 3 intranasal doses (4 mg each) of naloxone hydrochloride or IN saline will be administered to the subject on day 1. Plasma will be collected for measurement of naloxone concentrations on day 1 primary outcome is the difference in peak epinephrine secretion during the morning episodes of hypoglycemia on days one and two, thus each participant will have two observations: one from their naloxone experiment and one from their saline experiment.
Secondary endpoint will be naloxone pharmacokinetics including maximum concentration (Cmax), time to maximum concentration (Tmax) and area under the curve (AUC)
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55446
- Clinical and Translational Science Institute, University of Minnesota
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects are capable of giving informed consent.
- Female subjects must be post-menopausal for at least 1 year, or surgically incapable of bearing children, or practicing at least one or more of the following methods of contraception for three months prior to, and during the study: hormonal, intrauterine device (IUD), or barrier method in combination with a spermicide.
- Subject should be medication free, other than hormonal birth control, for 48 hours before through 24 hours after study drug administration. If the need for medication is identified during this time period, it will be discussed with and approved by the PI.
Exclusion Criteria:
- Women who are pregnant.
- Women who are breastfeeding.
- Subject has a known hypersensitivity to naloxone.
- Subject with hypertension
- Subject has a significant history of cardiac, neurologic, psychiatric, oncologic, endocrine, metabolic, renal or hepatic disease
- Subject has taken or used any investigational drug or device in the 30 days prior to screening.
- Subject has taken either prescribed or over the counter medication for 48 hours prior to study drug administration on either of the study days, other than hormonal birth control.
- History of narcotic or heroin abuse.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
3 doses of intra-nasal saline will be given during controlled hypoglycemic insulin clamps
|
3 doses of intra-nasal saline will be given during controlled hypoglycemic insulin clamps
|
Experimental: Treatment with intra-nasal Naloxone
3 doses of intra-nasal naloxone (4 mg each) will be given during controlled hypoglycemic insulin clamps
|
3 doses of intra-nasal naloxone (4 mg each) will be given during controlled hypoglycemic insulin clamps
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Within Person Difference in Peak Epinephrine During Hypoglycemia
Time Frame: 2 years
|
Primary endpoint will be the within person difference in peak epinephrine secretion during the morning episodes of hypoglycemia on days one and two; investigators will compare this difference between the two treatment conditions
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Naloxone Pharmacokinetics
Time Frame: 2 year
|
maximum concentration (Cmax)
|
2 year
|
Naloxone Pharmacokinetics
Time Frame: 2 year
|
area under the curve (AUC)
|
2 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Nervous System Diseases
- Immune System Diseases
- Autoimmune Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Endocrine System Diseases
- Diabetes Mellitus
- Consciousness Disorders
- Diabetes Mellitus, Type 1
- Hypoglycemia
- Unconsciousness
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Sensory System Agents
- Narcotic Antagonists
- Naloxone
Other Study ID Numbers
- 1103M96932
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on Intra-nasal saline
-
BeneChill, IncCompletedCardiac ArrestBelgium, Germany, Czech Republic, Italy, Sweden
-
Karolinska InstitutetKarolinska University Hospital; University Hospital, Lille; Erasme University... and other collaboratorsCompletedOut-of-hospital Cardiac ArrestBelgium, Sweden
-
Vanderbilt University Medical CenterCompleted
-
Lori WoodBarrow Brain and SpineRecruitingPituitary TumorUnited States
-
Istanbul UniversityRecruiting
-
PfizerCompletedSeasonal Allergic RhinitisUnited Kingdom
-
Viiral Nordic ABCompleted
-
Sun Yat-sen UniversityZhongshan People's Hospital, Guangdong, China; Fifth Affiliated Hospital of...RecruitingRadiation-Induced MucositisChina
-
Slagelse HospitalZealand University Hospital; Copenhagen University Hospital at Herlev; Holbaek... and other collaboratorsNot yet recruitingAsthma in Children | Bronchiolitis | Respiratory Disease | Acute Respiratory Infection | Viral Infection
-
University of FloridaCompleted